TABLE 1.
UC | Demographic and Clinical Characteristics |
---|---|
Sex | 11 F; 18 M (62%M and 38% F) |
Mean age ± SD (range) | 41± 15 (20–66) |
Disease duration median years (range) | 12 (1–38) |
Localization | |
Pancolitis (E3) | 25 (86%) |
Left colitis (E2) | 4 (15%) |
Proctosigmoiditis (E1) | 0 |
Mayo endoscopy score (MES) | |
Mayo 0 | 11 (38%) |
Mayo 1 | 8 (27.5%) |
Mayo 2 | 8 (27.5%) |
Mayo 3 | 2 (7%) |
Clinical Mayo | |
Remission < 2 remission | 15 (52%) |
Mild 2–4 mild activity | 7 (24%) |
Moderate 5–7 moderate activity | 3 (10%) |
Severe > 7 severe activity | 4 (14%) |
Biological therapy | |
Adalimumab | 3 (10.3%) |
Infliximab | 1 (3.5%) |
Vedolizumab | 3 (10.3%) |
Ustekinumab | 1 (3.5%) |
No biological therapy | 21 (72.4%) |
Medication | |
Mesalazine | 24 (83%) |
Steroids | 7 (24%) |
Immunosuppressants | 6 (20%) |
CRP mean (range) mg/dL | 9 (1–33) |
FC mean (range) mcg/gram | 656 (30–2363) |